Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure.

CONCLUSIONS: Comparing clinical improvement in both groups the decrease of acute phase reactants and the clinical remission measured by DAS28 was reached in both groups, however it was reached more belatedly in group 2 (at 6 months), this is due to the fact that they have more years of the disease evolution and a higher HAQ. PMID: 24179556 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/24179556?dopt=Abstract

Source: Open Rheumatology Journal - December 2, 2014 Category: Rheumatology Tags: Open Rheumatol J Source Type: research